Publique en esta revista
Información de la revista
Vol. 48. Núm. S1.
Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC)
Páginas 2-58 (Junio 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 48. Núm. S1.
Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC)
Páginas 2-58 (Junio 2012)
DOI: 10.1016/S0300-2896(12)70035-2
Acceso a texto completo
Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC)
Clinical Practice Guideline for the Diagnosis and Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) – Spanish Guideline for COPD (GesEPOC)
Visitas
...
Grupo de Trabajo de GesEPOC, Task Force of GesEPOC
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Miravitlles, M. Calle, J.J. Soler-Cataluña.
Clinical phenotypes of COPD. Identification, definition and implications for guidelines.
Arch Bronconeumol, 48 (2012), pp. 86-98
[2.]
J.B. Soriano, J. Zielinski, D. Price.
Screening for and early detection of chronic obstructive pulmonary disease.
[3.]
Estrategia en EPOC del Sistema Nacional de Salud.
Plan de Calidad para el Sistema Nacional de Salud.
Ministerio de Sanidad y Política Social, (2009),
[4.]
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Disponible en: http://www.goldcopd.org.
[5.]
G. Peces-Barba, J.A. Barberà, A. Agustí, C. Casanova, A. Casas, J.L. Izquierdo, et al.
Guía clínica de diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y Asociación Latinoamericana del Tórax (ALAT).
Arch Bronconeumol, 44 (2008), pp. 271-281
[6.]
Grupo de trabajo de la guía de práctica clínica sobre atención integral al paciente con enfermedad pulmonar obstructiva crónica (EPOC). Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y Sociedad Española de Medicina de Familia (semFYC); 2010.
[7.]
M.K. Han, A. Agustí, P.M. Calverley, B.R. Celli, G. Criner, J.L. Curtis, et al.
Chronic obstructive pulmonary disease phenotypes. The future of COPD.
Am J Respir Crit Care Med, 182 (2010), pp. 598-604
[8.]
M. Miravitlles.
Tratamiento individualizado de la EPOC: una propuesta de cambio.
Arch Bronconeumol, 45 (2009), pp. 27-34
[9.]
Grupo de trabajo GESEPOC.
Hacia un nuevo enfoque en el tratamiento de la EPOC. La Guía Española de la EPOC (GESEPOC).
Arch Bronconeumol, 47 (2011), pp. 379-381
[10.]
D. Anderson, W. MacNee.
Targeted treatment in COPD: a multi-system approach for a multi-system disease.
Int J Chron Obst Pulm Dis, 4 (2009), pp. 321-335
[11.]
Manual Metodológico para la elaboración de guías de práctica clínica del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo; 2007. Disponible en: http://www.guiasalud.es/emanuales/elaboracion/documentos/Manual%20metodologico%20%20Elaboracion%20GPC%20en%20el%20SNS.pdf.
[12.]
G. Guyatt, A.D. Oxman, E.A. Akl, R. Kunz, G. Vist, J. Brozek, et al.
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
J Clin Epidemiol, 64 (2011), pp. 383-394
[13.]
M. Marzo Castillejo, A. Montaño Barrientos.
El sistema GRADE para la toma de decisiones clínicas y la elaboración de recomendaciones y guías de práctica clínica.
Aten Primaria, 39 (2007), pp. 457-460
[14.]
G.H. Guyatt, A.D. Oxman, R. Kunz, J. Woodcock, J. Brozek, M. Helfand, et al.
GRADE guidelines: 8. Rating the quality of evidenced indirectness.
J Clin Epidemiol, 64 (2011), pp. 1303-1310
[15.]
J. Bousquet, J. Kiley, E.D. Bateman, G. Viegi, A.A. Cruz, N. Khaltaev, et al.
Prioritised research agenda for prevention and control of chronic respiratory diseases.
Eur Respir J, 36 (2010), pp. 995-1001
[16.]
A.S. Buist, M.A. McBurnie, W.M. Vollmer, S. Gillespie, P. Burney, D.M. Mannino, et al.
International variation in the prevalence of COPD (the BOLD study): a populationbased prevalence study.
[17.]
R.J. Halbert, J.L. Natoli, A. Gano, E. Badamgarav, A.S. Buist, D.M. Mannino.
Global burden of COPD: systematic review and meta-analysis.
Eur Respir J, 28 (2006), pp. 523-532
[18.]
K. Atsou, C. Chouaid, G. Hejblum.
Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.
[19.]
V.S. Sobradillo-Peña, M. Miravitlles, R. Gabriel, C.A. Jiménez- Ruiz, C. Villasante, J.F. Masa, et al.
Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study.
Chest, 118 (2000), pp. 981-989
[20.]
M. Miravitlles, M. Ferrer, A. Pont, J.L. Viejo, J.F. Masa, R. Gabriel, et al.
Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers.
Respir Med, 99 (2005), pp. 985-995
[21.]
M. Miravitlles, J.B. Soriano, F. García-Río, L. Muñoz, E. Duran-Taulería, G. Sánchez, et al.
Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities.
Thorax, 64 (2009), pp. 863-868
[22.]
J.B. Soriano, J. Ancochea, M. Miravitlles, F. García-Río, E. Duran, L. Muñoz, et al.
Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007.
Eur Respir J, 36 (2010), pp. 758-765
[23.]
WHO. World health statistics 2008. Disponible en: http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf. 2010.
[24.]
Regidor E, Gutiérrez-Fisac JL, Alfaro M. Patrón de mortalidad en España, 2008. Madrid: Ministerio de Sanidad, Política Social e Igualdad, 2011. Disponible en: http://www.msc.es/ca/estadEstudios/estadisticas/estadisticas/estMinisterio/mortalidad/docs/Patrones_de_Mortalidad_en_Espana_2008.pdf.
[25.]
Raziel: Mortalidad por todas las causas. Área de Análisis Epidemiológico y Situación de Salud. Disponible en: http://193.146.50.130/raziel.php.
[26.]
Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. Disponible en: http://www.msc.es/estadEstudios/estadisticas/cmbd.htm.
[27.]
Ministerio de Sanidad y Política Social. Plan de Calidad para el Sistema Nacional de Salud. Estrategia en EPOC del Sistema Nacional de Salud. Sanidad 2009. Ministerio de Sanidad y Política Social. Disponible en: http://www.msc.es/organizacion/sns/planCalidadSNS/docs/EstrategiaEPOCSNS.pdf.
[28.]
M. Miravitlles, C. Murio, T. Guerrero, R. Gisbert, on behalf of the DAFNE study group.
Costs of chronic bronchitis and COPD. A one year follow-up study.
Chest, 123 (2003), pp. 784-791
[29.]
J.J. Soler-Cataluña, M. Calle, B.G. Cosio, J.M. Marín, E. Monso, I. Alfageme.
Estándares de calidad asistencial en la EPOC.
Arch Bronconeumol, 45 (2009), pp. 361-362
[30.]
B.R. Celli, W. MacNee.
ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[31.]
B.R. Celli, N.E. Thomas, J.A. Anderson, G.T. Ferguson, C.R. Jenkins, P.W. Jones, et al.
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 178 (2008), pp. 332-338
[32.]
B.D. Patel, H.O. Coxson, S.G. Pillai, A.G.N. Agustí, P.M.A. Calverley, C.F. Donner, et al.
Airway wall thickening and emphysema show independente familial aggregation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 178 (2008), pp. 500-505
[33.]
F. Martínez-García, J.J. Soler-Cataluña, Y. Donat, P. Catalán, M. Agramunt, V. Ballestin, et al.
Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients.
Chest, 140 (2011), pp. 1130-1137
[34.]
J. Garcia-Aymerich, F.P. Gómez, M. Benet, E. Farrero, X. Basagaña, A. Gayete, et al.
Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) phenotypes.
Thorax, 66 (2011), pp. 430-437
[35.]
R. Vidal, I. Blanco, F. Casas, R. Jardí, M. Miravitlles.
Comité del Registro Nacional de Pacientes con Déficit de Alfa-1-antitripsina. Normativa SEPAR: Diagnóstico y tratamiento del déficit de alfa-1-antitripsina.
Arch Bronconeumol, 42 (2006), pp. 645-659
[36.]
J.R. Hurst, J. Vestbo, A. Anzeto, N. Locantore, H. Müllerova, R. Tal-Singer, et al.
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
N Engl J Med, 363 (2010), pp. 1128-1138
[37.]
J.J. Soler Cataluña, M.A. Martínez García, P. Catalán Serra.
The frequent exacerbator. A new phenotype in COPD?.
Hot Topics Respir Med, 6 (2011), pp. 7-12
[38.]
J.K. Quint, G.C. Donaldson, J.R. Hurst, J.J.P. Goldring, T.R. Seemungal, J.A. Wedzicha.
Predictive accuracy of patient-reported exacerbation frequency in COPD.
Eur Respir J, 37 (2011), pp. 501-507
[39.]
M. Bafadhel, S. McKenna, S. Terry, V. Mistry, C. Reid, P. Haldar, et al.
Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers.
Am J Respir Crit Care Med, 184 (2011), pp. 662-671
[40.]
P.G. Gibson, J.L. Simpson.
The overlap syndrome of asthma and COPD: what are its features and how important is it?.
Thorax, 64 (2009), pp. 728-735
[41.]
M. Contoli, S. Baraldo, B. Marku, P. Casolari, J.A. Marwick, G. Turato, et al.
Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: a 5-year follow-up.
J Allergy Cin Immunol, 125 (2010), pp. 830-837
[42.]
L.P. Boulet, C. Lemiere, F. Archambault, et al.
Smoking and asthma: clinical and radiological features, lung function, and airway inflammation.
Chest, 129 (2006), pp. 661-668
[43.]
D.E. O’Donnell, S. Aaron, J. Bourbeau, P. Hernandez, D.D. Marciniuk, M. Balter, et al.
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease: 2007 update.
Can Respir J, 14 (2007), pp. B:5B-B:B32
[44.]
A. Nagai, H. Aizawa, K. Aoshiba, K. Asano, K. Hirata, M. Ichinose, et al.
Guidelines for the diagnosis and treatment of COPD. The Japanese Respiratory Society.
3rd, Medical Review Co. Ltd, (2009),
[45.]
R. De Marco, S. Accordini, I. Cerveri, A. Corsico, J.M. Antó, N. Künzli, et al.
Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm.
Am J Respir Crit Care Med, 175 (2007), pp. 32-39
[46.]
M. Miravitlles.
The overlap síndrome between asthma and COPD: implications for management.
Hot Topics Respir Med, 16 (2011), pp. 15-20
[47.]
M. Hardin, E.K. Silverman, R.G. Barr, N.H. Hansel, J.D. Schroeder, B.J. Make.
The clinical features of the overlap between COPD and asthma.
Respir Res, 12 (2011), pp. 127
[48.]
J.B. Soriano, K.J. Davis, B. Coleman, G. Visick, D. Mannino, N.B. Pride.
The proportional Venn diagram of obstructive lung disease.
Chest, 124 (2003), pp. 474-481
[49.]
American Thoracic Society.
Chronic bronchitis, asthma, and pulmonary emphysema, a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases.
Am Rev Respir Dis, 85 (1962), pp. 762-768
[50.]
E. Prescott, P. Lange, J. Vestbo.
Chronic mucus hypersecretion in COPD and death from pulmonary infection.
Eur Respir J, 8 (1995), pp. 1333-1338
[51.]
M. Miravitlles.
Cough and sputum production as risk factors for poor outcomes in patients with COPD.
Respir Med, 105 (2011), pp. 1118-1128
[52.]
M. Montes de Oca, R.J. Halbert, M.V. López, R. Pérez-Padilla, C. Tálamo, D. Moreno, et al.
Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study.
[53.]
V. Kim, M.K. Han, G.B. Vance, B.J. Make, J.D. Newel, J.E. Hokanson, et al.
The chronic bronchitic phenotype of COPD. An analysis of the COPDGene study.
Chest, 140 (2011), pp. 626-633
[54.]
I.S. Patel, I. Vlahos, T.M.A. Wilkinson, S.J. Lloyd-Owen, G.C. Donaldson, M. Wilks, et al.
Bronchiectasis, exacerbation índices, and inflammation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 170 (2004), pp. 400-407
[55.]
C. Casanova, C. Cote, J.P. De Torres, A. Aguirre-Jaime, J.M. Marín, V. Pinto-Plata, et al.
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 171 (2005), pp. 591-597
[56.]
T.B. Grydeland, E. Thorsen, A. Dirksen, R. Jensen, H.O. Coxson, S.G. Pillai, et al.
Quantitative CT measures of emphysema and airway wall thickness are related to D(L)CO.
[57.]
M.K. Han, E.A. Kazerooni, D.A. Lynch, L.X. Liu, S. Murray, J.L. Curtis, et al.
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes.
Radiology, 261 (2011), pp. 274-282
[58.]
M. Nishimura, H. Makita, K. Nagai, S. Konno, Y. Nasuhara, M. Hasegawa, et al.
Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 185 (2012), pp. 44-52
[59.]
N.C. Oswald, V.C. Medvei.
Chronic bronchitis: the effect of cigarette-smoking.
Lancet, 269 (1955), pp. 843-844
[60.]
D. Anderson, B.G. Ferris Jr..
Role of tobacco smoking in the causation of chronic respiratory disease.
N Engl J Med, 267 (1962), pp. 787-794
[61.]
C. Fletcher, R. Peto.
The natural history of chronic airflow obstruction.
Br Med J, 1 (1977), pp. 1645-1648
[62.]
R. Kohansal, P. Martinez-Camblor, A. Agusti, A.S. Buist, D.M. Mannino, J.B. Soriano.
The natural history of chronic airflow obstruction revisited: an analysis of the Framingham off spring cohort.
Am J Respir Crit Care Med, 180 (2009), pp. 3-10
[63.]
A. Lokke, P. Lange, H. Scharling, P. Fabricius, J. Vestbo.
Developing COPD: a 25 year follows up study of the general population.
Thorax, 61 (2006), pp. 935-939
[64.]
Encuesta de salud de España. Disponible en: http://www.msc.es.
[65.]
S.S. Salvi, P.J. Barnes.
Chronic obstructive pulmonary disease in nonsmokers.
[66.]
M.S. Jaakkola, J.J. Jaakkola.
Effects of environmental tobacco smoke on the respiratory health of adults.
Scand J Work Environ Health, 28 (2002), pp. 52-70
[67.]
M.L. Larsson, H.M. Loit, M. Meren, J. Põlluste, A. Magnusson, K. Larsson, et al.
Passive smoking and respiratory symptoms in the FinEsS Study.
Eur Respir J, 21 (2003), pp. 672-676
[68.]
P. Yin, C.O. Jiang, K.K. Cheng, T.H. Lam, K.H. Lam, M.R. Miller, et al.
Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study.
[69.]
S.Y. Ho, T.H. Lam, S.F. Chung, T.P. Lam.
Cross-sectional and prospective associations between passive smoking and respiratory symptoms at the workplace.
Ann Epidemiol, 17 (2007), pp. 126-131
[70.]
F.J. González Barcala, B. Takkouche, L. Valdés, E. Temes, R. Leis, R. Cabanas, et al.
Tabaquismo parental y función pulmonar en niños y adolescentes.
Arch Bronconeumol, 43 (2007), pp. 81-85
[71.]
C. Torres-Duque, D. Maldonado, R. Pérez-Padilla, M. Ezzati, G. Viegi.
Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass. Exposure biomass fuels and respiratory diseases: a review of the evidence.
Proc Am Thorac Soc, 5 (2008), pp. 577
[72.]
G. Hu, Y. Zhou, J. Tian, W. Yao, J. Li, B. Li, et al.
Risk of COPD from exposure to biomass smoke: a metaanalysis.
Chest, 138 (2010), pp. 20-31
[73.]
O.P. Kurmi, S. Semple, P. Simkhada, W.C. Smith, J.G. Ayres.
COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis.
Thorax, 65 (2010), pp. 221-228
[74.]
J.Y. Po, J.M. FitzGerald, C. Carlsten.
Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis.
Thorax, 66 (2011), pp. 232-239
[75.]
M. Orozco-Levi, J. García-Aymerich, J. Villar, A. Ramírez-Sarmiento, J.M. Antó, J. Gea.
Wood smoke exposure and risk of chronic obstructive pulmonary disease.
Eur Respir J, 27 (2006), pp. 542-546
[76.]
M.D. Eisner, N. Anthonisen, D. Coultas, N. Kuenzli, R. Pérez-Padilla, D. Postma, et al.
Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 182 (2010), pp. 693-718
[77.]
M.A. Arbex, G.M. De Souza Conceição, S.P. Cendon, F.F. Arbex, A.C. Lopes, E.P. Moysés, et al.
Urban air pollution and COPD-related emergency room visits.
J Epidemiol Community Health, 63 (2009), pp. 777-783
[78.]
Z.J. Andersen, M. Hvidberg, S.S. Jensen, M. Ketzel, S. Loft, M. Sørensen, et al.
Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study.
Am J Respir Crit Care Med, 183 (2011), pp. 455-461
[79.]
EURAD [acceso 18 de mayo de 2011]. Disponible en: http://www.eurad.unikoeln.de/.
[80.]
L. Rushton.
Occupational causes of chronic obstructive pulmonary disease.
Rev Environ Health, 22 (2007), pp. 195-212
[81.]
E. Rodríguez, J. Ferrer, S. Martí, J.P. Zock, E. Plana, F. Morell.
Impact of occupational exposure on severity of COPD.
Chest, 134 (2008), pp. 1237-1243
[82.]
K.B. Lam, C.Q. Jiang, R.E. Jordan, M.R. Miller, W.S. Zhang, K.K. Cheng, et al.
Smoking and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study.
Chest, 137 (2010), pp. 593-600
[83.]
A.M.B. Menezes, P.C. Hallal, R. Perez-Padilla, J.R.B. Jardim, A. Muiño, M.V. Lopez, et al.
Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America.
Eur Respir J, 30 (2006), pp. 1180-1185
[84.]
Chronic obstructive pulmonary disease: risk factors and risk reduction [acceso julio 2009]. Disponible en: http://www.uptodate.com/online/.
[85.]
T. Kohnlein, T. Welte.
Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment.
[86.]
M. Miravitlles, C. Herr, I. Ferrarotti, R. Jardi, F. Rodriguez-Frias, M. Luisetti, et al.
Laboratory testing of individuals with severe AAT deficiency in three European centres.
Eur Respir J, 35 (2010), pp. 960-968
[87.]
D.M. Mannino, A.S. Buist.
Global burden of COPD: risk factors, prevalence, and future trends.
[88.]
N. Roche, R. Marthan, P. Berger, A. Chambellan, P. Chanez, B. Aguilaniu, et al.
Beyond corticosteroids: future prospects in the management of inflammation in COPD.
Eur Respir Rev, 20 (2011), pp. 175-182
[89.]
I.A. Yang, V. Relan, C.M. Wright, M.R. Davidson, K.B. Sriram, S.M. Savarimuthu Francis, et al.
Common pathogenic mechanisms and pathways in the development of COPD and lung cancer.
Expert Opin Ther Targets, 15 (2011), pp. 439-456
[90.]
W.M. Chatila, B.M. Thomashow, O.A. Minai, G.J. Criner, B.J. Make.
Comorbidities in chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 5 (2008), pp. 549-555
[91.]
P. Barnes, B.R. Celli.
Systemic manifestations and comorbidities in COPD.
Eur Respir J, 33 (2009), pp. 1165-1185
[92.]
J.B. Soriano, J. Sauleda, et al.
Chapter 12. How the COPD patient should be assessed for co-morbidities.
Clinical management of chronic obstructive lung disease, 2nd,
[93.]
P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, P.W. Jones, et al.
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
N Engl J Med, 356 (2007), pp. 775-789
[94.]
J.B. Soriano, G.T. Visick, H. Muellerova, N. Payvandi, A.L. Hansell.
Patterns of comorbidities in newly diagnosed COPD and asthma in primary care.
Chest, 128 (2005), pp. 2099-2107
[95.]
D.M. Mannino, D. Thorn, A. Swensen, F. Holguin.
Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease.
Eur Respir J, 32 (2008), pp. 962-969
[96.]
P. Almagro, F. López García, F.J. Cabrera, L. Montero, D. Morchón, J. Díez, et al.
Study of the comorbidities in hospitalized patients due to decompensated chronic obstructive pulmonary disease attended in the Internal Medicine Services. ECCO Study.
Rev Clin Esp, 210 (2010), pp. 101-108
[97.]
J. Finkelstein, E. Cha, S.M. Scharf.
Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity.
Int J Chron Obstruct Pulmon Dis, 4 (2009), pp. 337-349
[98.]
J.R. Feary, L.C. Rodrigues, C.J. Smith, R.B. Hubbard, J.E. Gibson.
Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care.
Thorax, 65 (2010), pp. 956-962
[99.]
G.C. Donaldson, J.R. Hurst, C.J. Smith, R.B. Hubbard, J.A. Wedzicha.
Increased risk of myocardial infarction and stroke following exacerbation of COPD.
Chest, 137 (2010), pp. 1091-1097
[100.]
F.H. Rutten, M.J. Cramer, D.E. Grobbee, A.P. Sachs, J.H. Kirkels, J.W. Lammers, et al.
Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease.
Eur Heart J, 26 (2005), pp. 1887-1894
[101.]
M.L. Render, A.S. Weinstein, A.S. Blaustein.
Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease.
Chest, 107 (1995), pp. 162-168
[102.]
P. Almagro, E. Calbo, A. Ochoa de Echagüen, B. Barreiro, S. Quintana, J.L. Heredia, et al.
Mortality after hospitalization for COPD.
Chest, 121 (2002), pp. 1441-1448
[103.]
R.G. Barr, D.A. Bluemke, F.S. Ahmed, J.J. Carr, P.L. Enright, E.A. Hoffman, et al.
Percent emphysema, airflow obstruction, and impaired left ventricular filling.
N Engl J Med, 362 (2010), pp. 217-227
[104.]
R.P. Young, R.J. Hopkins, T. Christmas, P.N. Black, P. Metcalf, G.D. Gamble.
COPD prevalence is increased in lung cancer, independent of age, sex and smoking history.
Eur Respir J, 34 (2009), pp. 380-386
[105.]
D.R. Brenner, J.R. McLaughlin, R.J. Hung.
Previous lung diseases and lung cancer risk: a systematic review and meta-analysis.
[106.]
A.M. Yohannes, T.G. Willgoss, R.C. Baldwin, M.J. Connolly.
Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles.
Int J Geriatr Psychiatry, 25 (2010), pp. 1209-1221
[107.]
T.P. Ng, M. Niti, W.C. Tan, Z. Cao, K.C. Ong, P. Eng.
Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life.
Arch Intern Med, 167 (2007), pp. 60-67
[108.]
E.M. Mortensen, L.A. Copeland, M.J. Pugh, M.I. Restrepo, R.M. De Molina, B. Nakashima, et al.
Impact of statins and ACE inhibitors on mortality after COPD exacerbations.
Respir Res, 10 (2009), pp. 45
[109.]
S. Salpeter, T. Ormiston, E. Salpeter.
Betabloqueantes cardioselectivos para la enfermedad pulmonar obstructiva crónica (Revisión Cochrane traducida).
La Biblioteca Cochrane Plus, (2008),
[110.]
P.M. Short, S.I. Lipworth, D.H. Elder, S. Schembri, B.J. Lipworth.
Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study.
Br Med J, 10 (2011), pp. d2549
[111.]
M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra, D.P. Tashkin, UPLIFT investigators.
Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Lancet, 374 (2009), pp. 1171-1178
[112.]
C.R. Jenkins, P.W. Jones, P.M. Calverley, et al.
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
Respir Res, 10 (2009), pp. 59
[113.]
G.C. Donaldson, T.A.R. Seemugal, A. Bhowmik, J.A. Wedzicha.
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax, 57 (2002), pp. 847-852
[114.]
J. Vestbo, E.D. Edwards, P.D. Scanlon, J.C. Yates, A. Agustí, P. Bakke, et al.
Changes in forced expiratory volume in 1 second over time in COPD.
N Engl J Med, 365 (2011), pp. 1184-1192
[115.]
S.I. Rennard, J.K. Stolel, K.C. Wilson.
Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging, (2011),
[116.]
J. Sanchís Aldás, P. Casan Clarà, J. Castillo Gómez, N. Honzález Mangado, L. Palenciano Ballesteros, J. Roca Torrent.
Normativa para la práctica de la espirometría forzada.
Arch Bronconeumol, 25 (1989), pp. 132-142
[117.]
M. Monteagudo, T. Rodriguez-Blanco, J. Parcet, N. Peñalver, C. Rubio, M. Ferrer, et al.
Variabilidad en la realización de la espirometría y sus consecuencias en el tratamiento de la EPOC en Atención Primaria.
Arch Bronconeumol, 47 (2011), pp. 226-233
[118.]
K. Naberan, C. De la Roza, M. Lamban, E. Gobartt, A. Martín, M. Miravitlles.
Use of spirometry in the diagnosis and treatment of chronic obstructive pulmonary disease in Primary Care.
Arch Bronconeumol, 42 (2006), pp. 638-644
[119.]
J.A. Hardie, A.S. Buist, W.M. Vollmer, I. Ellingsen, P.S. Bakke, O. Morkve.
Risk of overdiagnosis of COPD in asymptomatic elderly never-smokers.
Eur Respir J, 20 (2002), pp. 1117-1122
[120.]
B.R. Celli, R.J. Halbert, S. Isonaka, B. Schau.
Population impact of different definitions of airway obstruction.
Eur Respir J, 22 (2003), pp. 268-273
[121.]
R.A. Matthay, M.S. Niederman, H.P. Wiedemann.
Cardiovascular-pulmonary interaction in chronic obstructive pulmonary disease with special reference to the pathogenesis and management of cor pulmonale.
Med Clin North Am, 74 (1990), pp. 571
[122.]
R.G. Badgett, D.J. Tanaka, D.K. Hunt, et al.
Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone?.
Am J Med, 94 (1993), pp. 188
[123.]
M. Miniati, S. Monti, J. Stolk, G. Mirarchi, F. Falaschi, R. Rabinovich, et al.
Value of chest radiography in phenotyping chronic obstructive pulmonary disease.
Eur Respir J, 31 (2008), pp. 509-514
[124.]
T.B. Grydeland, A. Dirksen, H.O. Coxson, T.M.L. Eagan, E. Thorsen, S.G. PIllai, et al.
Quantitative computed tomography measures of emphysema and airway Wall thickness are related to respiratory symptoms.
Am J Respir Crit Care Med, 181 (2010), pp. 353-359
[125.]
G. Mair, J. Maclay, J.J. Miller, D. MacAllister, M. Connell, J.T. Murchison, et al.
Airway dimensions in COPD: relationship with clinical variables.
Respir Med, 104 (2010), pp. 1683-1690
[126.]
R. Yuan, J.C. Hogg, D.D. Sin, et al.
Prediction of the rate of decline in FEV1 in smokers using quantitative computed tomography.
Thorax, 64 (2009), pp. 944-949
[127.]
A. Haruna, S. Muro, Y. Nakano, T. Ohara, Y. Hoshino, E. Ogawa, et al.
CT scan findings of emphysema predict mortality in COPD.
Chest, 138 (2010), pp. 635-640
[128.]
M. Vendrell, J. De Gracia, C. Olveira, M.A. Martínez, R. Girón, L. Máiz, et al.
Diagnóstico y tratamiento de las bronquiectasias.
Arch Bronconeumol, 44 (2008), pp. 629-640
[129.]
M. John, S. Hoernig, W. Doehner, D.D. Okonko, C. Witt, S.D. Anker.
Anemia and inflammation in COPD.
Chest, 127 (2005), pp. 825-829
[130.]
Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.
Bull World Health Organ, 75 (1997), pp. 397-415
[131.]
Vilaró J. Prueba de la marcha de los 6 minutos. En: Burgos Rincón F, Casan Clará P, coordinadores. Manual de procedimientos SEPAR n.° 4: Procedimientos de evaluación de la función pulmonar-II. Madrid: SEPAR; 2004. p. 100-13.
[132.]
H. Boushey, P. Enright, J. Samet.
spirometry for chronic obstructive pulmonary disease case finding in primary care?.
Am J Respir Crit Care Med, 172 (2005), pp. 1481-1486
[133.]
T.J. Wilt, D. Niewoehner, C. Kim, et al.
Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Summary, Evidence Report/Technology Assessment: Number 121. AHRQ Publication Number 05-E017-1.
Agency for Healthcare Research and Quality, (2005),
[134.]
M. Miravitlles, C. Llor, E. Calvo, S. Díaz, H. Díaz-Cuervo, N. González-Rojas.
Validación de la versión traducida del chronic obstructive pulmonary disease-population screener (COPD-PS). Su utilidad y la del FEV1/FEV6 para el diagnóstico de EPOC.
Med Clin (Barc), (2012),
[135.]
F.J. Martinez, A.E. Raczek, F.D. Seifer, C.S. Conoscenti, T.G. Curtice, T. D’Eletto, et al.
Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS).
[136.]
C.P. Van Schayck, J.M.C. Loozen, E. Wagena, R.P. Akkermans, G.J. Wesseling.
Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study.
Br Med J, 324 (2002), pp. 1370
[137.]
M.J. Rodríguez Nieto, J. Galán Gallego, M. Martín García, A. Batanero, E. García, G. Peces-Barba.
Fiabilidad y facilidad de uso de un nuevo espirómetro portátil en el diagnóstico de la EPOC.
Rev Patol Respir, 14 (2011), pp. 53-89
[138.]
J.Y. Jing, T.C. Huang, W. Cui, F. Xu, H.H. Shen.
Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A meta-analysis.
Chest, 135 (2009), pp. 991-998
[139.]
C. Represas Represas, M. Botana Rial, V. Leiro Fernández, A.I. González Silva, V. Del Campo Pérez, A. Fernandez-Villar.
Validación del dispositivo portátil COPD-6 para la detección de patologías obstructivas de la vía aérea.
Arch Bronconeumol, 46 (2010), pp. 426-432
[140.]
J.J. Soler-Cataluña, B. Cosío, J.L. Izquierdo, J.L. López-Campos, J.M. Marín, R. Agüero, et al.
Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC.
Arch Bronconeumol, (2012),
[141.]
M. Miravitlles, A. Marin, E. Monsó, S. Vilà, C. De la Roza, R. Hervás, et al.
Colour of sputum is a marker of bacterial colonization in COPD.
Respir Res, 11 (2010), pp. 58
[142.]
B. Burrows, R.H. Earle.
Prediction of survival in patients with chronic airway obstruction.
Am Rev Respir Dis, 99 (1969), pp. 865-871
[143.]
K. Nishimura, T. Izumi, M. Tsukino, T. Oga.
en representación del Kansai COPD registry and research group in Japan. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.
Chest, 121 (2002), pp. 1434-1440
[144.]
V.M. Pinto-Plata, C. Cote, H. Cabral, J. Taylor, B.R. Celli.
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD.
Eur Respir J, 23 (2004), pp. 28-33
[145.]
B.R. Celli, C.G. Cote, J.M. Marín, C. Casanova, M. Montes de Oca, R.A. Mendez, et al.
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
N Engl J Med, 350 (2004), pp. 1005-1012
[146.]
K.C. Ong, A. Earnest, S.J. Lu.
A Multidimensional grading system (BODE Index) as predictor of hospitalization for COPD.
Chest, 128 (2005), pp. 3810-3816
[147.]
L. An, Y.X. Lin, T. Yang, H. Zhang, X. Jiao, S. Zhang, et al.
Predictive validity of BODE index for anxious and depressive symptoms in patients with chronic obstructive pulmonary disease.
Chin Med J, 123 (2010), pp. 1845-1851
[148.]
C.G. Cote, B.R. Celli.
Pulmonary rehabilitation and the BODE index in COPD.
Eur Respir J, 26 (2005), pp. 630-636
[149.]
S. Imfeld, K.E. Bloch, W. Weder, E.W. Russi.
The BODE index after lung volume reduction correlates with survival in COPD.
Chest, 129 (2006), pp. 835-836
[150.]
J.J. Soler-Cataluña, M.A. Martínez-García, L. Sánchez, M. Perpiña, P. Román.
Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients.
Respir Med, 103 (2009), pp. 692-699
[151.]
J.C. Bestall, E.A. Paul, R. Garrod, R. Garnham, P.W. Jones, J.A. Wedzicha.
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.
Thorax, 54 (1999), pp. 581-586
[152.]
C. Esteban, J.M. Quintana, M. Aburto, J. Moraza, M. Egurrola, J. Pérez-Izquierdo, et al.
Impact of changes in physical activity on health-related quality of life among patients with COPD.
Eur Respir J, 36 (2010), pp. 292-300
[153.]
J. García-Aymerich, P. Lange, M. Benet, P. Schnohr, J.M. Antó.
Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 175 (2007), pp. 458-463
[154.]
B. Waschki, A. Kirsten, O. Holz, K.C. Müller, T. Meyer, H. Watz, et al.
Physical activity is the strongest predictor of all-cause mortality in patients with COPD.
Chest, 140 (2011), pp. 331-342
[155.]
F. Pitta, T. Troosters, V.S. Probst, M.A. Spruit, M. Decramer, R. Gosselink.
Quantifying physical activity in daily life with questionnaires and motion sensors in COPD.
Eur Respir J, 27 (2006), pp. 1040-1055
[156.]
H. Watz, B. Waschki, T. Meyer, H. Magnussen.
Physical activity in patients with COPD.
Eur Respir J, 33 (2009), pp. 262-272
[157.]
J. García-Aymerich, I. Serra Pons, D.M. Mannino, A.K. Maas, D.P. Miller, K.J. Davis.
Lung function impairment, COPD hospitalisations and subsequent mortality.
Thorax, 66 (2011), pp. 585-590
[158.]
P.W. Jones, G. Harding, P. Berry, I. Wiklund, W.-H. Chen, N. Kline Leidy.
Development and first validation of the COPD Assessment Test.
Eur Respir J, 34 (2009), pp. 648-654
[159.]
P. Jones, G. Harding, I. Wiklund, P. Berry, N. Leidy.
Improving the process and outcome of care in COPD: development of a standardised assessment tool.
Prim Care Respir J, 18 (2009), pp. 208-215
[160.]
P. Jones, M. Tabberer, W.G. Chen.
Creating scenarios of the impact of COPD and their relationship to COPD asessment test (CATTM) socres.
BMC Pulm Med, 11 (2011), pp. 42
[161.]
P.W. Jones, G. Brusselle, R.W. Dal Negro, M. Ferrer, P. Kardos, M.L. Levy, et al.
Properties of the COPD assessment test in a cross-sectional European study.
Eur Respir J, 38 (2011), pp. 29-35
[162.]
N.R. Anthonisen, M.A. Skeans, R.A. Wise, J. Manfreda, R.E. Kanner, J.E. Connett.
The effects of a smoking cessation intervention on 14,5-year mortality: a randomized clinical trial.
Ann Intern Med, 142 (2005), pp. 233-239
[163.]
N.S. Godtfredsen, T.H. Lam, T.T. Hansel, M.E. Leon, N. Gray, C. Dresler, et al.
COPD related morbidity and mortality after smoking cessation: status of the evidence.
Eur Respir J, 32 (2008), pp. 844-853
[164.]
M.N. Hylkema, P.J. Sterk, W.I. De Boer, D.S. Postma.
Tobacco use in relation to COPD and asthma.
Eur Respir J, 29 (2007), pp. 438-445
[165.]
E.J. Wagena, M.P.A. Zeegers, C.P. Van Schayck, E.F.M. Wouters.
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.
Drug Saf, 26 (2003), pp. 381-403
[166.]
C.A. Jiménez Ruiz, J.I. De Granda Orive, J.A. Riesco Miranda.
Abordaje diagnóstico y terapéutico del tabaquismo en EPOC.
Tratado de rehabilitación respiratoria,
[167.]
C.A. Jiménez, F. Masa, M. Miravitlles, R. Gabriel, J.L. Viejo, C. Villasante, et al.
Smoking characteristics: attitudes and dependence. Differences between healthy smokers and smokers with COPD.
Chest, 119 (2001), pp. 1365-1373
[168.]
M.C. Fiore, C.R. Jaén, T.G. Baker, W.C. Bailey, N.L. Benowitz, S.J. Curry, et al.
Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline.
US Department of Health and Human Services, Public Health Service, (2008),
[169.]
D.P. Tashkin, S. Rennard, J. Taylor, Ma Wendy, D. Lawrence, T.C. Lee.
Effects of varenicline on smoking cessation in patients with mild to moderate COPD. A randomized controlled trial.
Chest, 139 (2011), pp. 591-599
[170.]
D. Postma, A. Anzueto, P. Calverley, C. Jenkins, B.J. Make, F.C. Sciurba, et al.
A new perspective on optimal care for patients with COPD.
Prim Care Respir J, 20 (2011), pp. 205-209
[171.]
P.J. Poole, E. Chacko, R.W. Wood-Baker, C.J. Cates.
Influenza vaccine for patients with chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2006),
[172.]
B. Michiels, F. Govaerts, R. Remmen, E. Vermeire, S. Coenen.
A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups.
Vaccine, 29 (2011), pp. 9159-9170
[173.]
J.A. Walters, S. Smith, P. Poole, R.H. Granger, R. Wood-Baker.
Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2010),
[174.]
I. Alfageme, R. Vazquez, N. Reyes, J. Muñoz, A. Fernández, M. Hernandez, et al.
Clinical efficacy of anti-pneumococcal vaccination inpatients with COPD.
Thorax, 61 (2006), pp. 189-195
[175.]
J.L. Lopez-Campos.
Estrategias de tratamiento en la enfermedad pulmonar obstructiva crónica: una propuesta de sistematización.
Arch Bronconeumol, 46 (2010), pp. 617-620
[176.]
P. Sestini, E. Renzoni, S. Robinson, P. Poole, F.S. Ram.
Short-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2002),
[177.]
G. Boyd, A.H. Morice, J.C. Pounsford, M. Siebert, N. Peslis, C. Crawford.
An evaluation of salmeterol in the treatment of the chronic obstructive pulmonary disease (COPD).
Eur Respir J, 10 (1997), pp. 815-821
[178.]
R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, et al.
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
Eur Respir J, 19 (2002), pp. 936-943
[179.]
R.A. Stockley, P.J. Whitehead, M.K. Williams.
Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.
Respir Res, 7 (2006), pp. 147
[180.]
D.P. Tashkin, C.B. Cooper.
The role of long-acting bronchodilators in the management of stable COPD.
Chest, 125 (2004), pp. 249-259
[181.]
J. Beier, K.M. Beeh.
Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol.
Int J Chron Obstruct Pulmon Dis, 6 (2011), pp. 237-243
[182.]
V. Brusasco, R. Hodder, M. Miravitlles, L. Korducki, L. Towse, S. Kesten.
Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD.
Thorax, 58 (2003), pp. 399-404
[183.]
J. O’Donnell, T. Flüge, F. Gerken, A. Hamilton, K. Webb, B. Aguilaniu, et al.
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
Eur Respir J, 23 (2004), pp. 832-840
[184.]
W.D.C. Man, N. Mustfa, D. Nikoletou, S. Kaul, N. Hart, G.F. Rafferty, et al.
Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD.
Thorax, 59 (2004), pp. 471-476
[185.]
B. Celli, M. Decramer, S. Kesten, D. Liu, S. Mehra, D.P. Tashkin.
Mortality in the 4-year trial of Tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 180 (2009), pp. 948-955
[186.]
M.A. Puhan, L.M. Bachmann, J. Kleijnen, G. Ter Riet, A.G. Kessels.
Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis.
[187.]
S. Appleton, T. Jones, P. Poole, L. Pilotto, R. Adams, T.J. Lasserson, et al.
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2006),
[188.]
S. Appleton, P. Poole, B. Smith, A. Veale, T.J. Lasserson, M.M. Chan.
Long-acting beta-2 agonists for poorly reversible chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, 3 (2006),
[189.]
T.J. Wilt, D. Niewoehner, R. MacDonald, R.L. Kane.
management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline.
Ann Intern Med, 147 (2007), pp. 639-653
[190.]
D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, et al.
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
N Engl J Med, 359 (2008), pp. 1543-1554
[191.]
C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P.M.H. Rutten van Molkën, K.M. Beeh, et al.
Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
N Engl J Med, 364 (2011), pp. 1093-1103
[192.]
R.G. Barr, J. Bourbeau, C.A. Camargo, F.S.F. Ram.
Tiotropium for stable chronic obstructive pulmonary disease: a metaanalysis.
Thorax, 61 (2006), pp. 854-862
[193.]
J.A. Van Noord, J.-L. Aumann, E. Janssens, J.J. Smeets, J. Verhaert, B. Disse, et al.
Comparison of tiotropium once daily, formoterol twice daily and both combined oncedaily in patients with COPD.
Eur Respir J, 26 (2005), pp. 214-222
[194.]
J.A. Van Noord, R. Buhl, C. LaForce, C. Martin, F. Jones, M. Dolker, et al.
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
Thorax, 65 (2010), pp. 1086-1091
[195.]
F.S.F. Ram, J.R. Jardim, A. Atallah, et al.
Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Respir Med, 99 (2005), pp. 135-144
[196.]
Y. Zhou, X. Wang, X. Zeng, R. Qiu, J. Xie, S. Liu, et al.
Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of lowdose, slow-release theophylline in the treatment of COPD for 1 year.
Respirology, 11 (2006), pp. 603-610
[197.]
American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency.
Am J Respir Crit Care Med, 168 (2003), pp. 818-900
[198.]
Task Force on COPD.
Moving towards a new focus on COPD. The Spanish COPD guidelines (GESEPOC).
Arch Bronconeumol, 47 (2011), pp. 379-381
[199.]
A. Papi, M. Romagnoli, S. Baraldo, et al.
Partial reversibility of airflow limitation and incresead exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 162 (2000), pp. 1773-1777
[200.]
M. Miravitlles.
Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity.
Arch Bronconeumol, 47 (2011), pp. 271
[201.]
R. Siva, R.H. Green, C.E. Brightling, M. Shelley, B. Hargadon, S. McKenna, et al.
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
Eur Respir J, 29 (2007), pp. 906-913
[202.]
GEMA 2009.
Guía Española para el Manejo del Asma 2009.
Arch Bronconeumol, 45 (2009), pp. 2-35
[203.]
T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, et al.
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 180 (2009), pp. 741-750
[204.]
S.P. Peters, S.J. Kunselman, M.A. Nikolina Icitovic, W.C. Moore, R. Pascual, B.T. Ameredes, et al.
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
N Engl J Med, 363 (2010), pp. 1715-1726
[205.]
American Thoracic Society.
Standards for diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 152 (1995), pp. 77-121
[206.]
K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, et al.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary.
Am J Respir Crit Care Med, 176 (2007), pp. 532-555
[207.]
P. Kardos, M. Wencker, T. Glaab, C. Vogelmeier.
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 175 (2007), pp. 144-149
[208.]
W. Szafransky, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, et al.
Efficacy and safety of budesonide/formoterol and formoterol in chronic obstructive pulmonary diseases.
Eur Respir J, 21 (2003), pp. 74-81
[209.]
L.J. Nannini, C.J. Cates, T.J. Lasserson, P. Poole.
Combined corticosteroid and longacting beta-agonistin one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2007),
[210.]
D.M. Sobieraj, C.M. White, C.I. Coleman.
Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a metaanalysis.
Clin Ther, 30 (2008), pp. 1416-1425
[211.]
A. Nieto, A. Mazon, R. Pamies, et al.
Adverse effects of inhaled corticosteroids in funded and nonfunded studies.
Arch Intern Med, 167 (2007), pp. 2047-2053
[212.]
P.D. Scanlon, J.E. Connett, R.A. Wise, et al.
Loss of bone density with inhaled triamcinolone in Lung Health Study II.
Am J Respir Crit Care Med, 170 (2004), pp. 1302-1309
[213.]
P.M.A. Calverley, F. Sanchez-Toril, A. McIvor, P. Teichmann, D. Bredenbroeker, L.M. Fabbri.
Effect of 1-year treatment with roflumilast in severe chronic obstructivepulmonary disease.
Am J Respir Crit Care Med, 176 (2007), pp. 154-161
[214.]
S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, et al.
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
Ann Intern Med, 146 (2007), pp. 545-555
[215.]
C. Karner, C.J. Cates.
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease.
Cochrane Database of Systematic Reviews, (2011),
[216.]
P.J. Barnes.
Theophylline for COPD.
Thorax, 61 (2006), pp. 742-744
[217.]
B.G. Cosio, L. Tsaprouni, K. Ito, E. Jazrawi, I.M. Adcock, P.J. Barnes.
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.
J Exp Med, 200 (2004), pp. 689-695
[218.]
L.M. Fabbri, P.M.A. Calverley, J.L. Izquierdo-Alonso, D.S. Bundschuh, M. Brose, F.J. Martinez, et al.
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials.
[219.]
E.D. Bateman, K.F. Rabe, P.M.A. Calverley, U.M. Goehring, M. Brose, D. Bredenbroker, et al.
Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history.
Eur Respir J, 38 (2011), pp. 553-560
[220.]
S.I. Rennard, P.M.A. Calverley, U.M. Goehring, et al.
Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD.
Respir Res, 12 (2011), pp. 18
[221.]
E.M. Grandjean, P. Berthet, R. Ruffmann, M. Leuenberger.
Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a metaanalysis of published double-blind, placebo-controlled clinical trials.
Clin Ther, 22 (2000), pp. 209-221
[222.]
E.R. Sutherland, J.D. Crapo, R.P. Bowler.
N-Acetylcysteine and exacerbations of chronic obstructive pulmonary disease.
COPD, 3 (2006), pp. 195-202
[223.]
P.J. Poole, P.N. Black.
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2006),
[224.]
J.P. Zheng, J. Kang, S.G. Huang.
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebocontrolled study.
Lancet, 371 (2008), pp. 2013-2018
[225.]
M. Decramer, M.M. Rutten-van, P.N. Dekhuijzen, T. Troosters, C. Van Herwaarden, R. Pellegrion, et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study. BRONCUS): a randomized placebo-controlled trial.
Lancet, 365 (2005), pp. 1552-1560
[226.]
T. Staykova, P.N. Black, E.E. Chacko, P. Poole.
Prophylactic antibiotic therapy for chronic bronchitis.
Cochrane Review, (2009),
[227.]
D. Sevilla-Sánchez, D. Soy-Muner, N. Soler-Porcar.
Utilidad de los macrólidos como antiinflamatorios en las enfermedades respiratorias.
Arch Bronconeumol, 46 (2010), pp. 244-254
[228.]
T.A.R. Seemungal, T.M.A. Wilkinson, J.R. Hurst, W.R. Perera, R.J. Sapsford, J.A. Wedzicha.
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
Am J Respir Crit Care Med, 178 (2008), pp. 1139-1147
[229.]
X. Pomares, C. Montón, M. Espasa, J. Casabon, E. Monsó, M. Gallego.
Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations.
Int J Chron Obst Respir Dis, 6 (2011), pp. 449-456
[230.]
R.K. Albert, J. Connett, W.C. Biley, R. Casaburi, J.A.D. Cooper, G.J. Criner, et al.
Azithromycin for prevention of exacerbations of COPD.
N Engl J Med, 365 (2011), pp. 689-698
[231.]
M. Miravitlles, A. Marín, E. Monsó, S. Vilà, C. De la Roza, R. Hervás, et al.
Efficacy of moxifloxacin in the treatment of bronchial colonization in COPD.
Eur Respir J, 34 (2009), pp. 1066-1071
[232.]
S. Sethi, P.W. Jones, M.S. Theron, M. Miravitlles, E. Rubinstein, J.A. Wedzicha, et al.
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
Respir Res, 11 (2010), pp. 10
[233.]
S. Sethi, T.F. Murphy.
Infection in the pathogenesis and course of chronic obstructive pulmonary disease.
N Engl J Med, 359 (2008), pp. 2355-2365
[234.]
S.G. Adams, A. Anzueto, D.D. Briggs Jr., I. Leimer, S. Kesten.
Evaluation of withdrawal of maintenance tiotropium in COPD.
Respir Med, 103 (2009), pp. 1415-1420
[235.]
P. Van der Valk, E. Monninkhof, J. Van del Palen, G. Zielhuis, C. Van Herwaarden.
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study.
Am J Respir Crit Care Med, 166 (2002), pp. 1358-1363
[236.]
J. Nighat, N.J. Nadeem, S. Taylor, S.M. Eldridge.
Withdrawal of inhaled corticosteroids in individuals with COPD: a systematic review and comment on trial methodology.
Respir Res, 12 (2011), pp. 107
[237.]
T.R.J. Schermer, A.J.C. Hendriks, N.H. Chavannes, P.N.R. Dekhuijzen, E.F.M. Wouters, H. Van der Hoogen, et al.
probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice.
Prim Care Respir J, 13 (2004), pp. 48-55
[238.]
J.J.W. Liesker, E. Bathoorn, D.S. Postma, J.M. Vonk, W. Timens, H.A.M. Kerstjens.
Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD.
Respir Med, 105 (2011), pp. 1853-1860
[239.]
J.M. Cranston, A.J. Crockett, J.R. Moss, J.H. Alpers.
Domiciliary oxygen for COPD.
Cochrane Database Syst Rev, (2005),
[240.]
Report of Medical Research Council Working Party.
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema.
Lancet, (1981), pp. 681-686
[241.]
Nocturnal Oxygen Therapy Trial Group.
Continuous of nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease.
An Intern Med, 93 (1980), pp. 391-398
[242.]
V. Kim, J.O. Benditt, R.A. Wise, A. Sharafkhaneh.
Oxygen therapy in chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 5 (2008), pp. 513-518
[243.]
E. Chailleux, B. Fauroux, F. Bidet, B. Dautzenberg, J.M. Polu.
Predictors of survival in patients receiving domiciliary oxigen therapy or mechanical ventilation. A 10- year analysis of ANTADIR Observatory.
Chest, 109 (1996), pp. 741-749
[244.]
D.E. O’Donell, C. D’Arsigny, K.A. Webb.
Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 163 (2001), pp. 892-898
[245.]
P.J. Wijkstra, G.H. Guyatt, N. Ambrosino, B.R. Celli, R. Güell, J.F. Muir, et al.
International approaches to the prescription of long-term oxygen therapy.
Eur Respir J, 18 (2001), pp. 909-913
[246.]
Atención integral al paciente con EPOC.
Desde la Atención Primaria a la Especializada.
Guía de práctica clínica, (2010),
[247.]
Guía de práctica clínica de diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. SEPAR-ALAT, 2009.
[248.]
J.M. Bradley, T. Lasserson, S. Elborn, J. Macmahon, B. O’Neill.
A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD.
Chest, 131 (2007), pp. 278-285
[249.]
J.M. Bradley, B. O’Neill.
Short-term ambulatory oxygen for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2005),
[250.]
M.A. Kolodziej, L. Jensen, B. Rowe, D. Sin.
Systematic review of noninvasive positive pressure ventilation in severe stable COPD.
Eur Respir J, 30 (2007), pp. 293-306
[251.]
R.D. McEvoy, R.J. Pierce, D. Hillman, et al.
Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial.
Thorax, 64 (2009), pp. 561-566
[252.]
S. Budweiser, R.A. Jörres, M. Pfeifer.
Treatment of respiratory failure in COPD.
Int J COPD, 3 (2008), pp. 605-618
[253.]
A. Goldberg, P. Leger, N. Hill, G. Criner.
Clinical indications for non-invasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease. OPD, and nocturnal hypoventilation. A consensus conference report.
Chest, 116 (1999), pp. 521-534
[254.]
P.C. Gay.
UptoDate.
Nocturnal ventilatory support in COPD, (2011),
[255.]
L. Nice, C.I. Donner, E. Wouters, et al.
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation.
Am J Respir Crit Care Med, 173 (2006), pp. 1390-1413
[256.]
ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel.
Pulmonary rehabilitation. Joint ACCP/AACVPR Evidence-Based Guidelines.
Chest, 131 (2007), pp. 4S-51S
[257.]
R. Güell, V. Resqueti, M. Sangenis, et al.
Impact of pulmonary rehabilitation on pshychosocial morbidity in patients with severe chronic obstructive pulmonary disease.
Chest, 129 (2006), pp. 899-904
[258.]
Y. Lacasse, R. Goldstein, T.J. Lasserson, S. Martin.
Pulmonary rehabilitation for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2006),
[259.]
F. Lötters, B. Van Tol, G. Kwakkel, et al.
Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis.
Eur Respir J, 20 (2002), pp. 570-576
[260.]
British Thoracic Society.
Standards of care subcommittee on pulmonary rehabilitation.
Thorax, 56 (2001), pp. 827-834
[261.]
M.K. Beauchamp, T. Janaudis-Ferreira, R.S. Goldstein, D. Brooks.
Optimal duration of pulmonary rehabilitation for individuals with chronic obstructive pulmonary disease: a systematic review.
Chron Respir Dis, 8 (2011), pp. 129-140
[262.]
A. Qaseem, T.J. Wilt, S.E. Weinberger, N.A. Hanania, G. Criner, T. Van der Molen, et al.
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians. American Thoracic Society, and European Respiratory Society.
Ann Intern Med, 155 (2011), pp. 179-191
[263.]
D.D. Marciniuk, D. Brooks, S. Butcher, R. Debigare, G. Dechman, G. Ford, Canadian Thoracic Society COPD Committee Expert Working Group, et al.
Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease--practical issues: a Canadian Thoracic Society Clinical Practice Guideline.
Can Respir J, 17 (2010), pp. 159-168
[264.]
N. Hopkinson, M. Polkey.
Does physical inactivity cause chronic obstructive pulmonary disease?.
Clin Sci, 118 (2010), pp. 565-572
[265.]
G. Grandes, A. Sánchez, R.O. Sánchez-Pinilla, J. Torcal, I. Montoya, K. Lizarraga, PEPAF Group, et al.
Effectiveness of physical activity advice and prescription by physicians in routine primary care: a cluster randomized trial.
Arch Intern Med, 169 (2009), pp. 694-701
[266.]
M.H. Ussher, A. Taylor, G. Faulkner.
Exercise interventions for smoking cessation.
Cochrane Database Syst Rev, (2008),
[267.]
M. Juan Díaz, A. Serrano Lázaro, A. Mesejo Arizmendi.
Aspectos nutricionales de la patología pulmonar.
Nutr Clin Med, 2 (2008), pp. 141-154
[268.]
S. Alcolea Batres, J. Villamor León, R. Álvarez-Sala.
EPOC y estado nutricional.
Arch Bronconeumol, 43 (2007), pp. 283-288
[269.]
C. Martín Salinas, T. Motilla Valeriano, Valoración del estado nutricional.
Nutrición y Dietética, 2.ª, pp. 301-319
[270.]
A. Martín Zurro, J.F. Cano Pérez.
Atención primaria: conceptos, organización y práctica clínica, pp. 991-1006
[271.]
F.J. Martinez.
Bullectomy for giant bullae in COPD, (2011),
[272.]
T.D. Christie, L.B. Edwards, P. Aurora, F. Dobbels, R. Kirk, A.O. Rahmel, et al.
Registry of the Internacional Society for Heart and Lung Transplantation Report-2008.
J Heart Lung Transplant, 27 (2008), pp. 957-969
[273.]
S. Lahzami, J.D. Aubert.
Lung transplantation for COPD- evidence-based?.
Swiss Med WKI, 139 (2009), pp. 4-8
[274.]
Normativa para la selección de pacientes candidatos a trasplante pulmonar.
Arch Bronconeumol, 47 (2011), pp. 303-309
[275.]
F.J. Martinez.
Lung volume reduction surgery in COPD. Uptodate, (2011),
[276.]
J. Reilly, G. Waskho, V. Pinto-Plata, E. Velez, L. Kenney, R. Berger, et al.
Biological lung volume reduction:a new bronchoscopic therapy for advance emphysema.
Chest, 131 (2007), pp. 1108-1113
[277.]
R.L. Berger, M.M. Decamp, G.J. Criner, B.R. Celli.
Lung volume reduction therapies for advanced emphysema: an update.
Chest, 138 (2010), pp. 407-417
[278.]
National Emphysema Treatment Trial Research Group.
Rationale and desing of the National Emphysema Treatment trial (NETT): a prospective randomized trial of lung volumen reduction surgery.
J Thorac Cardiovasc Surg, 118 (1999), pp. 518-528
[279.]
National Emphysema Treatment Trial Research.
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.
N Engl J Med, 348 (2003), pp. 2059-2073
[280.]
M.R. Güell, M.P. Cejudo, G. Rodríguez-Trigo, J.B. Gáldiz, V. Casolive, M. Reguerio, et al.
Estándares de calidad asistencial en rehabilitación respiratoria en pacientes con enfermedad pulmonar crónica.
Arch Bronconeumol, (2012),
[281.]
F. De Blasio, M. Polverino.
Current best practice in pulmonary rehabilitation for chronic obstructive pulmonary disease. Ther Adv Respir Dis.
PMID, (2012), pp. 22563010
[282.]
T.A.R. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, J.A. Wedzicha.
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 1418-1422
[283.]
L. Langsetmo, R.W. Platt, P. Ernst, J. Bourbeau.
Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort.
Am J Respir Crit Care Med, 177 (2008), pp. 396-401
[284.]
M. Miravitlles, M. Ferrer, A. Pont, R. Zalacaín, J.L. Álvarez-Sala, J.F. Masa, for the IMPAC study group, et al.
Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study.
Thorax, 59 (2004), pp. 387-395
[285.]
J.R. Hurst, G.C. Donaldson, W.R. Perera, T.M. Wilkinson, J.A. Bilello, G.W. Hagan, et al.
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 174 (2006), pp. 867-874
[286.]
C.M. Parker, N. Voduc, S.D. Aaron, K.A. Webb, D.E. O’Donnell.
Physiologic changes during symptom recovery from moderate exacerbation of COPD.
Eur Respir J, 26 (2005), pp. 420-428
[287.]
W.R. Perera, J.R. Hurst, T.M.A. Wilkinson, R.J. Sapsford, H. Müllerova, G.C. Donaldson, et al.
Inflammatory changes, recovery and recurrence at COPD exacerbation.
Eur Respir J, 29 (2007), pp. 527-534
[288.]
J.J. Soler-Cataluña, M.A. Martínez-García, P. Román-Sanchez, E. Salcedo, M. Navarro, R. Ochando.
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.
Thorax, 60 (2005), pp. 925-931
[289.]
F. Abroug, L. Quanes-Besbes, N. Nciri, N. Sellami, F. Addad, K. Ben Hamda, et al.
Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disaase. Diagnostic performance of cardiac biomarkers.
Am J Respir Crit Care Med, 174 (2006), pp. 990-996
[290.]
C.L. Chang, S.C. Robinson, G.D. Mills, G.D. Sullivan, N.C. Karalus, J.D. McLachlan, et al.
Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD.
Thorax, 66 (2011), pp. 764-768
[291.]
E. Sapey, A. Stockley.
COPD exacerbations: aetiology.
Thorax, 61 (2006), pp. 250-258
[292.]
A. Papi, C.M. Bellettato, F. Braccioni, M. Romagnoli, P. Casolari, G. Caramori, et al.
Infections of airway inflammation in chronic obstructive pulmonary disease severe exacerbations.
Am J Respir Crit Care Med, 173 (2006), pp. 1114-1121
[293.]
M. Miravitlles, C. Espinosa, E. Fernández-Laso, J.A. Martos, J.A. Maldonado, M. Gallego, and Study Group of Bacterial Infection in COPD.
Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD.
Chest, 116 (1999), pp. 40-46
[294.]
N.R. Anthonisen, J. Manfreda, C.P. Warren, E.S. Hershfield, G.K. Harding, N.A. Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[295.]
R.A. Stockley, C. O’Brien, A. Pye, S.L. Hill.
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.
Chest, 117 (2000), pp. 1638-1645
[296.]
N. Soler, C. Agustí, J. Angrill, J. Puig de la Bellacasa, A. Torres.
Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.
Thorax, 62 (2007), pp. 29-35
[297.]
S. Tokmas, P. Schuetz, S. Bent.
Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations.
Expert Rev Anti Infect Ther, 9 (2011), pp. 727-735
[298.]
J.M. Daniels, M. Schoorl, D. Snijders, et al.
Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD.
Chest, 138 (2010), pp. 1108-1115
[299.]
J. Rizkallah, S.F. Man, D.D. Sin.
Prevalence of pulmonary embolism in acute exacerbation of COPD: a systematic review and metaanalysis.
Chest, 135 (2009), pp. 786-793
[300.]
F. Uresandi, J. Blanquer, F. Conget, M.A. De Gregorio, J.L. Lobo, R. Otero, et al.
Guía para el diagnóstico, tratamiento y seguimiento de la tromboembolia pulmonar.
Arch Bronconeumol, (2004), pp. 580-594
[301.]
D.C. McCrory, C. Brown, S.E. Gelfand, P.B. Bach.
Management of acute exacerbations of COPD: a summary and appraisal of published evidence.
Chest, 119 (2001), pp. 1190-1209
[302.]
M.O. Turner, A. Patel, S. Ginsburg, J.M. FitzGerald.
Bronchodilator delivery in acute airflow obstruction. A meta-analysis.
Arch Intern Med, 157 (1997), pp. 1736-1744
[303.]
J. Boe, J.H. Dennis, B.R. O’Driscoll, et al.
European Respiratory Society Guidelines on the use of nebulizers.
Eur Respir J, 18 (2001), pp. 228-242
[304.]
F. Di Marco, M. Verga, P. Santus, N. Morelli, M. Cazzola, S. Centanni.
Effect of formoterol, tiotropium, and their combination in patients with acute exacerbations of chronic obstructive pulmonary disease: a pilot study.
Respir Med, 100 (2006), pp. 1925-1932
[305.]
R.G. Barr, B.H. Rowe, C.A. Camargo.
Methylxanthines for exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2003),
[306.]
S. Nouira, S. Marghli, M. Belghith, L. Besbes, S. Elatrous, F. Abroug.
Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.
Lancet, 358 (2001), pp. 2020-2025
[307.]
M. Miravitlles, E. Monsó, J. Mensa, J. Aguarón Pérez, J. Barberán, M. Bárcena Caamaño, et al.
Tratamiento antimicrobiano de la agudización de EPOC: Documento de Consenso 2007.
Arch Bronconeumol, 44 (2008), pp. 100-108
[308.]
J.M. Singh, V.A. Palda, M.B. Stanbrook, K.R. Chapman.
Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review.
Arch Intern Med, 162 (2002), pp. 2527-2536
[309.]
J.A. Walters, P.G. Gibson, R. Wood-Baker, M. Hannay, E.H. Walters.
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2009),
[310.]
R.K. Albert, T.R. Martin, S.W. Lewis.
Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency.
Ann Intern Med, 92 (1980), pp. 753-758
[311.]
L. Davies, R.M. Angus, P.M. Calverley.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
Lancet, 354 (1999), pp. 456-460
[312.]
H. Gunen, S.S. Hacievliyagil, O. Yetkin, G. Gulban, L.C.E. Mutly.
The role of neublized budesonide in the treatment of exacerbations of COPD.
Eur Respir J, 29 (2007), pp. 660-667
[313.]
F. Maltais, J. Ostinelli, J. Bourbeau, A.B. Tonnel, N. Jacquemet, J. Haddon, et al.
Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
Am J Respir Crit Care Med, 165 (2002), pp. 698-703
[314.]
R. Otero, E. Grau, D. Jiménez, F. Uresandi, J.L. López, E. Calderón, et al.
Profilaxis de la enfermedad tromboémbólica venosa.
Arch Bronconeumol, 44 (2008), pp. 160-169
[315.]
M.A. Puhan, E. Gimeno-Santos, M. Scharplatz, T. Troosters, E.H. Walters, J. Steurer.
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2011),
[316.]
C. Burtin, M. Decramer, R. Gosselink, W. Janssens, T. Troosters.
Rehabilitation and acute exacerbations.
Eur Respir Dis, 38 (2011), pp. 702-712
[317.]
J.V. Lightowler, J.A. Wedzicha, M.W. Elliott, F.S. Ram.
Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.
Br Med J, 326 (2003), pp. 185-187
[318.]
C. Hernandez, A. Casas, J. Escarrabill, J. Alonso, J. Puig-Junoy, E. Farrero, et al.
Home hospitalization of exacerbated chronic obstructive pulmonary disease patients.
Eur Respir J, 21 (2003), pp. 58-67
[319.]
F.S. Ram, J.A. Wedzicha, J. Wright, M. Greenstone.
Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence.
Br Med J, 329 (2004), pp. 315
[320.]
National Cancer Institute. Disponible en: http://www.cancer.gov/.
[321.]
J.R. Curtis.
Palliative and end-of-life care for patients with severe COPD.
Eur Respir J, 32 (2008), pp. 796-803
[322.]
J.S. Temel, J.A. Greer, A. Muzikansky, et al.
Early palliative care for patients with metastatic non-small-cell lung cancer.
N Engl J Med, 363 (2010), pp. 733-742
[323.]
J.M. Gore, C.J. Brophy, M.A. Greenstone.
How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)?. A comparison of palliative care and quality of life in COPD and lung cancer.
Thorax, 55 (2000), pp. 1000-1006
[324.]
K.E. Steinhauser, R.M. Arnold, M.K. Olsen, J. Lindquist, J. Hays, L.L. Wood, et al.
Comparing three life-limiting diseases: does diagnosis matter or is sick, sick?.
J Pain Symptom Manage, 42 (2011), pp. 331-341
[325.]
C. Bausewein, S. Booth, M. Gysels, et al.
Understanding breathlessness: crosssectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer.
J Palliat Med, 13 (2010), pp. 1109-1118
[326.]
V. Lohne, H.C. Heer, M. Andersen, et al.
Qualitative study of pain of patients with chronic obstructive pulmonary disease.
Heart Lung, 39 (2010), pp. 226-234
[327.]
R. Horton, G. Rocker.
Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease.
Curr Opin Support Palliat Care, 4 (2010), pp. 56-62
[328.]
H. Pinnock, M. Kendall, S.A. Murray, et al.
Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study.
Br Med J, (2011), pp. d142
[329.]
N. Small, C. Gardiner, S. Barnes, et al.
Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease.
Palliat Med, 24 (2010), pp. 740
[330.]
K. Hardin, F. Meyers, S. Louie.
Integrating palliative care in severe chronic obstructive lung disease.
[331.]
C. Bausewein, S. Booth, M. Gysels, I. Higginson.
Nonpharmacological interventions for breathlessness in advanced stages of malignant and nonmalignant diseases.
Cochrane Database Syst Rev, (2008),
[332.]
A.L. Jennings, A.N. Davies, J.P. Higgins, et al.
A systematic review of the use of opioids in the management of dyspnoea.
Thorax, 57 (2002), pp. 939-944
[333.]
A.P. Abernethy, D.C. Currow, P. Frith, et al.
Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea.
Br Med J, 327 (2003), pp. 523-528
[334.]
A.L. Jennings, A.N. Davies, J.P.T. Higgins, K. Broadley.
Tratamiento paliativo con opiáceos para la disnea de la enfermedad terminal (Revisión Cochrane traducida). Biblioteca Cochrane Plus.
Update Software Ltd, (2008),
[335.]
D. Goodridge, J. Lawson, G. Rocker, D. Marciniuk, D. Rennie.
Factors associated with opioid dispensation for patients with COPD and lung cancer in the last year of life: a retrospective analysis.
Int J Chron Obstruct Pulmon Dis, 5 (2010), pp. 99-105
[336.]
B. Varkey.
Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients.
Curr Opin Pulm Med, 16 (2010), pp. 150-154
[337.]
S.T. Simon, I.J. Higginson, S. Booth, et al.
Benzodiazepinas para el alivio de la disnea en adultos con enfermedades malignas y benignas. Biblioteca Cochrane Plus.
Update Software Ltd, (2010),
[338.]
H. Putman-Casdorph, S. McCrone.
Chronic obstructive pulmonary disease, anxiety, and depression: state of the science.
Heart Lung, 38 (2009), pp. 34-47
[339.]
Sociedad Española de Cuidados Paliativos. Cuidados paliativos: la familia de la persona enferma. Disponible en: http://www.secpal.com/guiasm/index. php?acc=see_guia&id_guia=4.
[340.]
Normativas SEPAR: Recomendaciones sobre la atención al final de la vida en pacientes con EPOC. Disponible en: http://www.separ.es/publicaciones/normativa/normativa_052.html.
[341.]
J. Escarrabill, J.J. Soler Cataluña, C. Hernández, et al.
Recommendations for End-of- Life Care in Patients With Chronic Obstructive Pulmonary Disease.
Arch Bronconeumol, 45 (2009), pp. 297-303
[342.]
M.E. Romero Roy, J.F. Jimeno Salgado.
Yoga y EPOC. Abordaje desde las técnicas respiratorias.
Medicina Naturista, (2007), pp. 30-35
[343.]
W. Hutton.
Putting the public at the heart of the NHS.
Br Med J, 334 (2007), pp. 69-70
[344.]
Health literacy: report of the Council on Scientific Affairs.
Ad Hoc Committee on Health Literacy for the Council on Scientific Affairs, American Medical Association.
JAMA, 281 (1999), pp. 552-557
[345.]
D.A. Dewalt, N.D. Berkman, S. Sheridan, K.N. Lohr, M.P. Pignone.
Literacy and health outcomes: a systematic review of the literature.
J Gen Intern Med, 19 (2004), pp. 1228-1239
[346.]
C.R. Selden, M. Zorn, S.C. Ratzan.
Health literacy, (2011),
[347.]
D.A. Dewalt, M.P. Pignone.
The role of literacy in health and health care.
Am Fam Physician, 72 (2005), pp. 387-388
[348.]
P. Easton, V.A. Entwistle, B. Williams.
Health in the ‘hidden population’ of people with low literacy. A systematic review of the literature.
BMC Public Health, 10 (2010), pp. 459
[349.]
B.J. Powers, J.V. Trinh, H.B. Bosworth.
Can this patient read and understand written health information?.
JAMA, 304 (2010), pp. 76-84
[350.]
N.J. Roberts, R. Ghiassi, M.R. Partridge.
Health literacy in COPD.
Int J Chron Obstruct Pulmon Dis, 3 (2008), pp. 499-507
[351.]
T.C. Davis, M.S. Wolf.
Health literacy: implications for family medicine.
Fam Med, 36 (2004), pp. 595-598
[352.]
D.W. Baker, R.M. Parker, M.V. Williams, K. Pitkin, N.S. Parikh, W. Coates, et al.
The health care experience of patients with low literacy.
Arch Fam Med, 5 (1996), pp. 329-334
[353.]
R.S. Safeer, J. Keenan.
Health literacy: the gap between physicians and patients.
Am Fam Physician, 72 (2005), pp. 463-468
[354.]
S.G. Adams, P.K. Smith, P.F. Allan, A. Anzueto, J.A. Pugh, J.E. Cornell.
Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management.
Arch Intern Med, 167 (2007), pp. 551-561
[355.]
J. Bourbeau, J. Van der Palen.
Promoting effective self-management programmes to improve COPD.
Eur Respir J, 33 (2009), pp. 461-463
[356.]
T. Bodenheimer, K. MacGregor, C. Sharifi.
Helping patients manage their chronic conditions.
California Healthcare Foundation, (2005),
[357.]
L.B. Mauksch, D.C. Dugdale, S. Dodson, R. Epstein.
Relationship, Communication, and Efficiency in the Medical Encounter.
Arch Intern Med, 168 (2008), pp. 1387-1395
[358.]
W. Langewitz, M. Denz, A. Keller, A. Kiss, S. Rüttimann, B. Wössmer.
Spontaneous talking time at start of consultation in outpatient clinic: cohort study.
Br Med J, 325 (2002), pp. 682-683
[359.]
J.L. Hanson.
Shared decision making. Have we missed the obvious?.
Arch Intern Med, 168 (2008), pp. 1368-1370
[360.]
J. Bourbeau, M. Julien, F. Maltais, M. Rouleau, A. Beaupré, R. Bégin, et al.
Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.
Arch Intern Med, 163 (2003), pp. 585-591
[361.]
B. De Vries, C. Darling-Fisher, A.C. Thomas, E.B. Belanger-Shugart.
Implementation and outcomes of group medical appointments in an outpatient specialty care clinic.
J Am Acad Nurse Pract, 20 (2008), pp. 163-169
[362.]
R. Jaber, A. Braksmajer, J. Trilling, Group visits for chronic illness care: models, benefits and challenges.
Fam Pract Manag, 13 (2006), pp. 37-40
[363.]
E.W. Bischoff, D.H. Hamd, M. Sedeno, A. Benedetti, T.R. Schermer, S. Bernard, et al.
Effects of written action plan adherence on COPD exacerbation recovery.
Thorax, 66 (2011), pp. 26-31
[364.]
Universidad de los pacientes [accedido 7 May 2011]. Disponible en: http://www.universidadpacientes.org/kitdevisitamedica/elkit/index.php?pag=descarga.
[365.]
A. Jovell, M. Navarro Rubio, L. Fernández Maldonado, S. Blancafort.
Nuevo rol del paciente en el sistema sanitario.
Aten Primaria, 38 (2006), pp. 234-237
[366.]
The Expert Patient A New Approach to Chronic Disease Managementfor the 21st Century [accedido 8 May 2011]. Disponible en: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4018578.pdf.
[367.]
A. González Mestre, N. Fabrellas Padrés, M. Agramunt Perelló, E. Rodríguez Pérez, E. Grifell Martín.
De paciente pasivo a paciente activo.
Programa Paciente Experto del Institut Català de la Salut. Revista de Innovación Sanitaria y Atención Integrada, 1 (2008),
[368.]
K. Lorig.
Partnerships between expert patients and physicians.
[369.]
K.R. Lorig, P.L. Ritter, A. Dost, K. Plant, D.D. Laurent, I. McNeil.
The Expert Patients Programme online, a 1-year study of an Internet-based self-management programme for people with long-term conditions.
Chronic Illn, 4 (2008), pp. 247-256
[370.]
M. Martí, N. Fabrellas, S. Chicote, V. Escribano, A. Raventós, N. Padilla.
Llamada al autocuidado. Seguimiento telefónico a enfermedades crónicas.
Revista de Innovación Sanitaria y Atención Integrada, 1 (2008),
[371.]
A. Marshall, O. Medvedev, A. Antonov.
Use of a smartphone for improved selfmanagement of pulmonary rehabilitation.
Int J Telemed Appl, 75 (2008), pp. 30-64
[372.]
P. De Toledo, S. Jiménez, F. Del Pozo, J. Roca, A. Alonso, C. Hernandez.
Telemedicine experience for chronic care in COPD.
IEEE Transactions on Information Technology in Biomedicine, 10 (2006), pp. 567-573
[373.]
E. Torrente, J. Escarrabill, T. Martí.
Impacto de las redes sociales de pacientes en la práctica asistencial.
Revista de Innovación Sanitaria y Atención Integrada, 2 (2010),
[374.]
D. Tapscott, D. Williams.
Wikinomics.
Atlantic Books, (2006),
Copyright © 2012. Sociedad Española de Neumología y Cirugía Torácica
Idiomas
Archivos de Bronconeumología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.